Nanomedicine, Antibodies, Antibody-Drug Conjugates (ADCs), cathepsin proteases, cancer, inflammation, infection

Professor Chris Scott is Acting Director of the Centre for Cancer Research and Cell Biology at Queen’s University Belfast.  Following a primary degree in Biochemistry he undertook a PhD and post doctoral training at Queen’s in molecular enzymology.  In 2001, Chris was one of the founding members of QUB spinout company Fusion Antibodies Ltd., before returning to Queen’s in 2003 to take up an academic position.  Chris is internationally renowned for his work in development of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions.  Work in his laboratory is funded by agencies such as Medical Research Council, HSCNI, and various industrial sources such as AstraZeneca and Immunocore.  He also held a Royal Society Industrial Fellowship with GSK from 2012-15, and won the Vice Chancellor’s Prize for Innovation in 2015 with his group’s work on developing a novel nanomedicine for the treatment of sepsis and other inflammatory conditions. Chris is actively involved in nanomedicine across the UK and is a Trustee of the British Society of Nanomedicine.